|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:abuseDeterrent
|
yes
|
|
gptkbp:activeIngredient
|
gptkb:hydrocodone_bitartrate
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:ATCCode
|
N02AA05
|
|
gptkbp:blackBoxWarning
|
accidental ingestion
addiction, abuse, and misuse
interaction with alcohol
life-threatening respiratory depression
neonatal opioid withdrawal syndrome
|
|
gptkbp:contraindication
|
known or suspected gastrointestinal obstruction
acute or severe bronchial asthma
significant respiratory depression
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_II_(US)
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:drugClass
|
opioid
|
|
gptkbp:form
|
120 mg
20 mg
100 mg
40 mg
80 mg
extended-release tablet
30 mg
60 mg
|
|
gptkbp:halfLife
|
7-9 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Hysingla ER
|
|
gptkbp:indication
|
pain management
|
|
gptkbp:legalStatus
|
prescription only (Rx)
|
|
gptkbp:manufacturer
|
gptkb:Purdue_Pharma
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
constipation
dizziness
headache
pruritus
drowsiness
|
|
gptkbp:bfsParent
|
gptkb:Purdue_Pharma
|
|
gptkbp:bfsLayer
|
6
|